<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905746</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0020</org_study_id>
    <secondary_id>2019-A00266-51</secondary_id>
    <nct_id>NCT03905746</nct_id>
  </id_info>
  <brief_title>Study of microRNAs in a Decompensated Cirrhosis</brief_title>
  <acronym>EmiC</acronym>
  <official_title>Expression and Variance of microRNAs in a Cohort of Patients With Acute Decompensation of Cirrhosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune&#xD;
      responses. Septic complications represent a major issue in the management of cirrhotic&#xD;
      patients, with a 1-month mortality rate of 23%, which increases to 80% at 3 months in case of&#xD;
      associated organ failure.&#xD;
&#xD;
      Delay to treatment initiation during a septic episode may increase the risk of complications&#xD;
      and mortality of cirrhotic patients. However, the inappropriate use of antibiotics exposes&#xD;
      cirrhotic patients to the risk of more severe infections due to multi-resistant organisms or&#xD;
      fungi.&#xD;
&#xD;
      The use of diagnostic markers for sepsis is limited in the context of cirrhosis because of&#xD;
      the lack of hepatic synthesis of these markers on the one hand and non-specific inflammation&#xD;
      related to cirrhosis on the other hand.&#xD;
&#xD;
      Therefore, it is necessary to develop new tools for the early diagnosis of sepsis and&#xD;
      appropriate management of cirrhotic patients.&#xD;
&#xD;
      The interest of microRNAs (miRNAs) in the diagnosis and prognosis of septic shock has been&#xD;
      reported in the general population. No studies have described circulating miRNAs or reported&#xD;
      their interest in the diagnosis of sepsis in a population of cirrhotic patients with acute&#xD;
      decompensation (AD).&#xD;
&#xD;
      This preliminary study of 800 circulating miRNAs will be performed in a cohort of patients&#xD;
      with acute cirrhosis decompensation, for whom the incidence of sepsis is estimated at 40%.&#xD;
      The aim to evaluate the interest and feasibility of a larger study on the interest of&#xD;
      circulating miRNAs in the early diagnosis of sepsis in cirrhotic patients. The long-term&#xD;
      objective of this study is the development of biomarkers for the early management of&#xD;
      cirrhotic patients with sepsis and the rationalization of antibiotic use to improve their&#xD;
      prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">December 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of 800 miRNA between the 2 subgroups of the AD group according to the retrospective diagnosis of sepsis or not</measure>
    <time_frame>Day 0</time_frame>
    <description>The difference of miRNAs levels will assess in patients recruited in the AD group who will be retrospectively diagnosed as septic at the time of enrollment and compare them non septic patients.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Acute Decompensation</condition>
  <arm_group>
    <arm_group_label>acute decompensation group</arm_group_label>
    <description>patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pathological control group</arm_group_label>
    <description>patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample at Day 0</intervention_name>
    <description>40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.&#xD;
(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)</description>
    <arm_group_label>Pathological control group</arm_group_label>
    <arm_group_label>acute decompensation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample at Day 2 and Day 7</intervention_name>
    <description>20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.</description>
    <arm_group_label>acute decompensation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool sample at Day 0</intervention_name>
    <description>stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.</description>
    <arm_group_label>Pathological control group</arm_group_label>
    <arm_group_label>acute decompensation group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and peripheral blood mononuclear cells (PBMCs) will be collected at D0, D2 and D7 from&#xD;
      enrolment.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients concerned are cirrhotic patients, followed in the hepatology department of Pr&#xD;
        Zoulim and in department of Pr Souquet (Croix Rousse Hospital, North Hospital Group,&#xD;
        Hospices Civils de Lyon), without a history of cancer or active infection with the virus of&#xD;
        the hepatitis B, hepatitis C virus or HIV.&#xD;
&#xD;
        2 groups will be formed:&#xD;
&#xD;
          -  A group of cirrhotic patients with acute decompensation (AD group)&#xD;
&#xD;
          -  A group of stable cirrhotic patients (pathological controls)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cirrhosis (determined either by histopathology or by association of&#xD;
             clinical signs of portal hypertension and hepatocellular insufficiency and&#xD;
             radiological signs (dysmorphic liver, evidences of portal hypertension (collateral&#xD;
             circulation, ascites)).&#xD;
&#xD;
        AND&#xD;
&#xD;
          -  Not refusing his / her participation in the study after information (or non-opposition&#xD;
             of the person of confidence if the patient has a disorder of consciousness or impaired&#xD;
             judgment (hepatic encephalopathy) at the time of inclusion) AND&#xD;
&#xD;
          -  Admitted within 48 hours for an episode of acute decompensation (acute decompensation&#xD;
             group = AD group), which is defined by the sudden occurrence of one or more of the&#xD;
             following clinical or biological symptoms:&#xD;
&#xD;
               -  Jaundice&#xD;
&#xD;
               -  Hepatic encephalopathy&#xD;
&#xD;
               -  oedemato-ascitic decompensation&#xD;
&#xD;
               -  Gastro-intestinal bleeding&#xD;
&#xD;
               -  Acute renal failure (according to AKIN criteria (22)) and / or hyponatremia&#xD;
&#xD;
               -  Degradation of hepatocellular functions (decrease of prothrombin time and factor&#xD;
                  V measured in blood, increase of bilirubinemia) OR&#xD;
&#xD;
          -  Outpatient follow-up for stable cirrhosis, not admitted in the last 6 months for an&#xD;
             episode of acute cirrhosis decompensation (pathological control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor or major patient under guardianship or curatorship&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patient deprived of liberty&#xD;
&#xD;
          -  History of extra-digestive cancer&#xD;
&#xD;
          -  History of hepatocellular carcinoma or other hepatobiliary cancer&#xD;
&#xD;
          -  Chronic infection with Hepatitis B virus (defined by the presence of Antibodies to&#xD;
             hepatitis B core antigen (anti-HBc) and the absence of Hepatitis B surface antibodies&#xD;
             (anti-HBs)) identified by a recent serology (less than 6 months)&#xD;
&#xD;
          -  Chronic Hepatitis C Virus infection or cured for less than 6 months&#xD;
&#xD;
          -  Infection with the Human Immunodeficiency Virus identified by a recent serology (less&#xD;
             than 6 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fanny Lebossé, PhD</last_name>
    <phone>04 26 10 93 39</phone>
    <phone_ext>+33</phone_ext>
    <email>Fanny.lebosse@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Lebossé, PhD</last_name>
      <phone>04 26 10 93 39</phone>
      <phone_ext>+33</phone_ext>
      <email>Fanny.lebosse@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Fanny Lebossé, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe SOUQUET, PU,PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

